Fig. 6: Selective inhibition of 13 anti-PAR4 IgG and IgM antibodies on PAR4-mediated human platelet aggregation. | npj Vaccines

Fig. 6: Selective inhibition of 13 anti-PAR4 IgG and IgM antibodies on PAR4-mediated human platelet aggregation.

From: To generate functional anti-protease-activated receptor-4 (PAR4), a G protein-coupled receptor, antibodies through PAR4-mRNA-LNP immunization

Fig. 6: Selective inhibition of 13 anti-PAR4 IgG and IgM antibodies on PAR4-mediated human platelet aggregation.

To determine whether the functional anti-PAR4 antibodies can inhibit platelet aggregation, A human platelet suspensions were pretreated with 13 supernatants from the hybridoma cells for 3 min and stimulated with PAR4-AP (100 μM). Five clones (8-9B, 1F-2B, 12A-6D, 12A-9B, and 12A-10E) were identified as capable of inhibiting platelet aggregation and acting as PAR4 antagonists. B To confirm the specificity of the five clones for PAR4 versus other platelet-agonist receptors, PAR1-AP was used. They all showed an inhibitory effect of less than 20% or did not affect PAR1-AP-induced platelet aggregation. Control: FO cell culture medium. Values are presented as the mean ± S.E.M. (n ≥ 3). *P < 0.05, **P < 0.01, ***P < 0.001, compared with the control.

Back to article page